CoChat

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations

Open access
Litichevskiy, Lev, Peckner, Ryan, Abelin, Jennifer G., Asiedu, Jacob K., Creech, Amanda L., Davis, John F., Davison, Desiree, Dunning, Caitlin M., Egertson, Jarrett D., Egri, Shawn, Gould, Joshua, Ko, Tak, Johnson, Sarah A., Lahr, David L., Lam, Daniel, Liu, Zihan, Lyons, Nicholas J., Lu, Xiaodong, MacLean, Brendan X., Mungenast, Alison E., Officer, Adam, Natoli, Ted E., Papanastasiou, Malvina, Patel, Jinal, Sharma, Vagisha, Toder, Courtney, Tubelli, Andrew A., Young, Jennie Z., Carr, Steven A., Golub, Todd R., Subramanian, Aravind, MacCoss, Michael J., Tsai, Li-Huei, Jaffe, Jacob D. · 2018 · Cell Systems

Published version of a preprint

Cited by 87

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Although the value of proteomics has been demonstrated, cost and scale are typically prohibitive, and gene expression profiling remains dominant for characterizing cellular responses to perturbations. However, high-throughput sentinel assays provide an opportunity for proteomics to contribute at a meaningful scale. We present a systematic library resource (90 drugs × 6 cell lines) of proteomic signatures that measure changes in the reduced-representation phosphoproteome (P100) and changes in epigenetic marks on histones (GCP). A majority of these drugs elicited reproducible signatures, but notable cell line- and assay-specific differences were observed. Using the "connectivity" framework, we compared signatures across cell types and integrated data across assays, including a transcriptional assay (L1000). Consistent connectivity among cell types revealed cellular responses that transcended lineage, and consistent connectivity among assays revealed unexpected associations between drugs. We further leveraged the resource against public data to formulate hypotheses for treatment of multiple myeloma and acute lymphocytic leukemia. This resource is publicly available at https://clue.io/proteomics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cels.2018.03.012

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 57

  1. Abelin, 2016, Reduced-representation phosphosignatures measured by quantitative targeted ms capture cellular states and enable large-scale comparison of drug-induced phenotypes, Mol. Cell. Proteomics, 15, 1622, 10.1074/mcp.M116.058354 · DOI · Paper page
  2. Alizadeh, 2000, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, 403, 503, 10.1038/35000501 · DOI · Paper page
  3. Araf, 2016, Epigenetic dysregulation in follicular lymphoma, Epigenomics, 8, 77, 10.2217/epi.15.96 · DOI
  4. Ashenden, 2017, An in vivo functional screen identifies JNK signaling as a modulator of chemotherapeutic response in breast cancer, Mol. Cancer Ther., 16, 1967, 10.1158/1535-7163.MCT-16-0731 · DOI
  5. Aumann, 2014, Somatic alterations and dysregulation of epigenetic modifiers in cancers, Biochem. Biophys. Res. Commun., 455, 24, 10.1016/j.bbrc.2014.08.004 · DOI
  6. Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page
  7. Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  8. Baur, 2006, Therapeutic potential of resveratrol: the in vivo evidence, Nat. Rev. Drug Discov., 5, 493, 10.1038/nrd2060 · DOI · Paper page
  9. Bhanu, 2016, Histone modification profiling reveals differential signatures associated with human embryonic stem cell self-renewal and differentiation, Proteomics, 16, 448, 10.1002/pmic.201500231 · DOI
  10. Bian, 2014, An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome, J. Proteomics, 96, 253, 10.1016/j.jprot.2013.11.014 · DOI · Paper page
  11. Bittner, 2000, Molecular classification of cutaneous malignant melanoma by gene expression profiling, Nature, 406, 536, 10.1038/35020115 · DOI · Paper page
  12. Bridges, 2016, MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells, Oncotarget, 7, 71660, 10.18632/oncotarget.12311 · DOI
  13. Bryant, 2014, Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers, BMC Cancer, 14, 570, 10.1186/1471-2407-14-570 · DOI
  14. Ciceri, 2014, Dual kinase-bromodomain inhibitors for rationally designed polypharmacology, Nat. Chem. Biol., 10, 305, 10.1038/nchembio.1471 · DOI · Paper page
  15. Clark, 2000, Genomic analysis of metastasis reveals an essential role for RhoC, Nature, 406, 532, 10.1038/35020106 · DOI · Paper page
  16. Creech, 2015, Building the Connectivity Map of epigenetics: chromatin profiling by quantitative targeted mass spectrometry, Methods, 72, 57, 10.1016/j.ymeth.2014.10.033 · DOI · Paper page
  17. Dawson, 2012, Targeting epigenetic readers in cancer, N. Engl. J. Med., 367, 647, 10.1056/NEJMra1112635 · DOI · Paper page
  18. Fabian, 2005, A small molecule-kinase interaction map for clinical kinase inhibitors, Nat. Biotechnol., 23, 329, 10.1038/nbt1068 · DOI · Paper page
  19. Golub, 1999, Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, Science, 286, 531, 10.1126/science.286.5439.531 · DOI · Paper page
  20. Gräff, 2009, Epigenetic dysregulation in cognitive disorders, Eur. J. Neurosci., 30, 1, 10.1111/j.1460-9568.2009.06787.x · DOI · Paper page
  21. Gupta, 2013, Cancer drug discovery by repurposing: teaching new tricks to old dogs, Trends Pharmacol. Sci., 34, 508, 10.1016/j.tips.2013.06.005 · DOI · Paper page
  22. Iacovelli, 2015, Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia, Oncotarget, 6, 32089, 10.18632/oncotarget.5156 · DOI
  23. Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 · DOI · Paper page
  24. Jaffe, 2013, Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia, Nat. Genet., 45, 1386, 10.1038/ng.2777 · DOI · Paper page
  25. Jenuwein, 2001, Translating the histone code, Science, 293, 1074, 10.1126/science.1063127 · DOI · Paper page
  26. Kelly, 2010, Epigenetic modifications as therapeutic targets, Nat. Biotechnol., 28, 1069, 10.1038/nbt.1678 · DOI · Paper page
  27. Kulej, 2015, Characterization of histone post-translational modifications during virus infection using mass spectrometry-based proteomics, Methods, 90, 8, 10.1016/j.ymeth.2015.06.008 · DOI
  28. Lamb, 2003, JunD mediates survival signaling by the JNK signal transduction pathway, Mol. Cell, 11, 1479, 10.1016/S1097-2765(03)00203-X · DOI · Paper page
  29. Laubach, 2017, Deacetylase inhibitors: an advance in myeloma therapy?, Expert Rev. Hematol., 10, 229, 10.1080/17474086.2017.1280388 · DOI
  30. Lee, 2008, Ahnak protein activates protein kinase C (PKC) through dissociation of the PKC-protein phosphatase 2A complex, J. Biol. Chem., 283, 6312, 10.1074/jbc.M706878200 · DOI
  31. Li, 2017, Characterization of human cancer cell lines by reverse-phase protein arrays, Cancer Cell, 31, 225, 10.1016/j.ccell.2017.01.005 · DOI · Paper page
  32. Luense, 2016, Comprehensive analysis of histone post-translational modifications in mouse and human male germ cells, Epigenetics Chromatin, 9, 24, 10.1186/s13072-016-0072-6 · DOI
  33. Martin, 2005, The diverse functions of histone lysine methylation, Nat. Rev. Mol. Cell Biol., 6, 838, 10.1038/nrm1761 · DOI · Paper page
  34. Ntziachristos, 2016, Emerging concepts of epigenetic dysregulation in hematological malignancies, Nat. Immunol., 17, 1016, 10.1038/ni.3517 · DOI · Paper page
  35. Ott, 2012, BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia, Blood, 120, 2843, 10.1182/blood-2012-02-413021 · DOI · Paper page
  36. Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J. Clin. Oncol., 27, 1160, 10.1200/JCO.2008.18.1370 · DOI · Paper page
  37. Peck, 2010, SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2, Mol. Cancer Ther., 9, 844, 10.1158/1535-7163.MCT-09-0971 · DOI · Paper page
  38. Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 · DOI · Paper page
  39. Qin, 2015, DNA methylation requires a DNMT1 ubiquitin interacting motif (UIM) and histone ubiquitination, Cell Res., 25, 911, 10.1038/cr.2015.72 · DOI · Paper page
  40. Rohban, 2017, Systematic morphological profiling of human gene and allele function via Cell Painting, Elife, 6, 10.7554/eLife.24060 · DOI · Paper page
  41. Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 · DOI · Paper page
  42. Sharma, 2014, Panorama: a targeted proteomics knowledge base, J. Proteome Res., 13, 4205, 10.1021/pr5006636 · DOI · Paper page
  43. Shi, 2016, Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia, J. Hematol. Oncol., 9, 12, 10.1186/s13045-016-0241-x · DOI
  44. Sidoli, 2015, Sequential window acquisition of all theoretical mass spectra (SWATH) analysis for characterization and quantification of histone post-translational modifications, Mol. Cell. Proteomics, 14, 2420, 10.1074/mcp.O114.046102 · DOI · Paper page
  45. Smith, 2017, Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map, PLoS Biol., 15, e2003213, 10.1371/journal.pbio.2003213 · DOI · Paper page
  46. Steiner, 2017, Carfilzomib boosted combination therapy for relapsed multiple myeloma, Onco. Targets Ther., 10, 895, 10.2147/OTT.S102756 · DOI
  47. Suzuki, 2006, Pvclust: an R package for assessing the uncertainty in hierarchical clustering, Bioinformatics, 22, 1540, 10.1093/bioinformatics/btl117 · DOI · Paper page
  48. Tasian, 2017, Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia, Blood, 129, 177, 10.1182/blood-2016-05-707653 · DOI · Paper page
  49. van der Maaten, 2008, Visualizing data using t-SNE, J. Mach. Learn. Res., 9, 2579
  50. Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J. Clin. Oncol., 29, 3085, 10.1200/JCO.2010.33.2312 · DOI · Paper page
  51. Wendling, 2013, Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis, Clin. Epigenetics, 5, 10, 10.1186/1868-7083-5-10 · DOI
  52. Wernig, 2008, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera, Cancer Cell, 13, 311, 10.1016/j.ccr.2008.02.009 · DOI · Paper page
  53. Whitesell, 2003, The stress response: implications for the clinical development of hsp90 inhibitors, Curr. Cancer Drug Targets, 3, 349, 10.2174/1568009033481787 · DOI · Paper page
  54. Witzig, 2015, The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma, Blood, 126, 328, 10.1182/blood-2015-02-629543 · DOI
  55. Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci., 36, 422, 10.1016/j.tips.2015.04.005 · DOI · Paper page
  56. Yazgan, 2002, Regulation of two JunD isoforms by Jun N-terminal kinases, J. Biol. Chem., 277, 29710, 10.1074/jbc.M204552200 · DOI · Paper page
  57. Zhou, 2013, Toward a comprehensive characterization of a human cancer cell phosphoproteome, J. Proteome Res., 12, 260, 10.1021/pr300630k · DOI · Paper page

Cited by

Metadata

Authors
Litichevskiy, L., Peckner, R., Abelin, J. G., Asiedu, J. K., Creech, A. L., Davis, J. F., Davison, D., Dunning, C. M., Egertson, J. D., Egri, S., Gould, J., Ko, T., Johnson, S. A., Lahr, D. L., Lam, D., Liu, Z., Lyons, N. J., Lu, X., MacLean, B. X., Mungenast, A. E., Officer, A., Natoli, T. E., Papanastasiou, M., Patel, J., Sharma, V., Toder, C., Tubelli, A. A., Young, J. Z., Carr, S. A., Golub, T. R., Subramanian, A., MacCoss, M. J., Tsai, L.-H., & Jaffe, J. D.
Venue
Cell Systems
Publisher
Elsevier BV
Published
2018-04
Volume
6
Issue
4
Pages
424-443.e7
ISSN
2405-4712 (ISSN-L)
OpenAlex
W2751974426
Cited by
87
References
16
FWCI
4.83
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
NIH (U54HG008097, U54HG008699)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.